Inactive Instrument

Highlights InterCure Ltd. TEL AVIV STOCK EXCHANGE

Equities

InterCure Ltd. Provides Revenue Guidance for the Full Year 2024	May. 01	CI
InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	May. 01	CI
InterCure Ltd. Provides Earnings Guidance for the Second Half and Full Year of 2023	Apr. 01	CI
InterCure Ltd. Expects to Launch Its First Products in Germany in the Coming Months	Mar. 22	CI
InterCure Ltd. entered into a share purchase agreement to acquire Leon Pharm Ltd for ILS 8.3 million.	Jan. 30	CI
InterCure Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
InterCure Provides Update About Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger	23-06-12	MT
InterCure Ltd. entered into an agreement to acquire 51% stake in Orni Pharmacy Ltd.	22-11-15	CI
InterCure to Launch Trading on Nasdaq Wednesday	21-09-01	MT
InterCure Ltd. Announces Earnings Results for the Second Quarter Ended June 30, 2021	21-08-16	CI
InterCure Provided Update on Its NASDAQ Listing	21-07-12	MT
InterCure Ltd signed a Letter of Intent to acquire Cann Pharmaceutical Ltd. for $35 million.	21-04-04	CI
InterCure Ltd. completed the acquisition of additional 7.43% stake in Regenera Pharma Ltd. from Bamot Investments Ltd.	16-09-26	CI
InterCure Ltd. signed an agreement to acquire additional 7.43% stake in Regenera Pharma Ltd. from Bamot Investments Ltd. for ILS 3 million.	16-09-10	CI

No results for this search